medigraphic.com

2004, Número s2

<< Anterior Siguiente >>

Arch Cardiol Mex 2004; 74 (s2)


El índice de flujo TIMI/perfusión en el infarto agudo del miocardio sin elevación del segmento ST. Un auxiliar eficaz en la valoración de los regímenes de reperfusión con y sin tirofiban

Martínez RMA, Rosas M, González H, Peña DMA, Martínez SC, Gaspar J, García H, Gaxiola E, Delgado L, Carrillo J, Leyva JL, Lupi E

Idioma: Ingles.
Referencias bibliográficas: 33
Paginas: 394-405
Archivo PDF: 126.62 Kb.


RESUMEN

Más allá de una reperfusión epicárdica exitosa, la reperfusión miocárdica para la elevación de la onda ST, requiere también de un restablecimiento completo del flujo sanguíneo en la microvasculatura coronaria. En este estudio, el tirofiban como terapia conjunta en los regímenes de lisis y de stent, no sólo mejoró el flujo de reperfusión epicárdica, sino también las velocidades de tales reperfusiones, los cuales fueron relacionados con un mejor resultado clínico sin incrementar el riesgo de un sangrado importante. Este estudio apoya la hipótesis del papel fundamental de las plaquetas no solamente en el proceso aterotrombótico, sino también en otros eventos. Por ello, se propone que el índice de reperfusión epicárdica/índice de perfusión sea empleado en el análisis de todo nuevo régimen de reperfusión.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. TIMI Study Group: The Thrombolysis in Myocardial Infarction (TIMI) Trial: phase I findings. N Engl J Med 1985; 312: 932-936.

  2. Lee KL, Woodlief LH, Topol EJ, et al: Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction: results from international trial of 41,021 patients. Circulation 1995; 91: 1659-1668.

  3. Armstrong PW, Granger C, Van de Werf F: Bolus Fibrinolysis: Risk, benefit, and opportunities. Circulation 2001; 103: 1171-1173.

  4. Rezkalla SH, Kloner RA: No-Reflow Phenomenon. Circulation 2002; 105: 656-662.

  5. Sutton AGC, Campell PG, Grech ED, et al: Failure of thrombolysis: experience with a policy of early angiography and rescue angioplasty for electrocardiographic evidence of failed thrombolysis. Heart 2000; 84: 197-204.

  6. de Belder MA: Acute Myocardial Infarction: Failed Thrombolysis. Heart 2001; 85: 104-112.

  7. Kucia MA, Jame CZ: Failed reperfusion after thrombolytic therapy recognition and management. Heart & Lung 2002; 31: 113-121.

  8. Davies CH, Ormerod OJM: Failed coronary thrombolysis. Lancet 1998; 351: 1191-1196.

  9. Cannon CP: Overcoming thrombolytic resistance. Rationale and initial experience combining thrombolytic therapy and glycoprotein IIb/IIIa receptor inhibition for acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1395-1402.

  10. Gibson MC: Primary angioplasty compared with thrombolysis: New issues in the era of glycoprotein IIb/IIIa inhibition and coronary stenting. Ann Intern Med 1999; 130: 841-847.

  11. Watson DSR, Chin BSP, Lip GYH: Antithrombotic therapy in acute coronary syndromes. BMJ 2002; 325: 1358-1355.

  12. Ohman EM, Kleiman NS, Gacioch G, et al: Combined Accelerated Tissue-Plasminogen Activator and Platelet Glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997; 95: 846-854.

  13. Antman EM, Giugliano RP, Gibson MC, et al: Abciximab facilitates the rate and extent of thrombolysis. Results of the thrombolysis in myocardial infarction (TIMI) 14 trial. Circulation 1999; 99: 2720-2732.

  14. de Lemos JA, Antman EM, Gibson MC, et al: Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from TIMI 14 trial. Circulation 2000; 101: 239-243.

  15. Brener SJ, Zeymer U, Adgey JAA, et al: Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction. The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002; 39: 377-386.

  16. Veselka J, Tesar D, Mates M: Coronary stenting without predilatation: a clinical routine with Jomed Delivery System Catheter Cardiovasc Interv. 1999; 46(1):121-2.

  17. Gulba DC, Tanswell P, Dechend R, et al: Six-Minute Alteplase Protocol: A New Accelerated Recombinant Tissue-type Plasminogen Activator Regimen for Thrombolysis in Acute Myocardial Infarction. J Am Coll Cardiol 1997; 30: 1611-7.

  18. The GUSTO angiographic investigators: The effects of tissue plasminogen activatior, streptokinase, or both on coronary patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993; 329: 1615-1622.

  19. Gibson CM, Cannon CP, Murphy SA, et al: For the TIMI study group. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000; 101: 125-130.

  20. Gibson MC, Cannon CP, Murphy SA, et al: Relationship of the TIMI myocardial perfusion grades, flow grades, frame count, and percutaneous coronary intervention to long-term outcomes after thrombolytic administration in acute myocardial infarction. Circulation 2002; 105: 1909-1913.

  21. Neuhaus KL, Jeep-Teebe S, Niederer W, et al: Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activatior. J Am Coll Cardiol 1989; 14: 1566-1569.

  22. Bailar JC III, Mosteller F, eds. Medical uses of statistics. 2nd ed. Waltham, Mass.: NEJM Books, 1992: 261-9, 281-291.

  23. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187-220.

  24. Fergusson D, Aaron SD, Guyatt G, et al: Post-randomization exclusions: the intention to treat principle and excluding patients from analysis. BMJ 2002; 325: 652-654.

  25. Schomig A, Kastrati A, Dirschinger J, et al: Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000; 343: 385-391.

  26. Stone GW, Grines CL, Cox DA, et al: Comparison of angioplasty with stenting with or without abciximab, in acute myocardial infarction (CADILLAC) investigators. N Engl J Med 2002; 346: 957-966.

  27. Topol EJ: Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998; 97: 211-218.

  28. Van de Werf F, Baim DS: Reperfusion for ST-segment elevation myocardial infarction: An overview of current treatment options. Circulation 2002; 105: 2813-2816.

  29. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomized trials. Lancet 2003; 361: 13-20.

  30. Ruggeri ZM: Platelets in atherothrombosis. Nature Medicine 2002; 8: 1227-1234.

  31. Leclerc JR. Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions. Crit Care Med 2002; 30(Suppl.): S332-S340.

  32. Boersma E, Harrington RA, Moliterno DJ, et al: Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomized clinical trials. Lancet 2002; 359: 189-198.

  33. Ellis SG, Sliva ER, Heyndrickx G, et al: For the RESCUE investigators. Randomized comparison of rescue angioplasty with conservative management of patients with early failure of thrombolysis for acute myocardial infarction. Circulation 1994; 90: 2280-2284.




2020     |     www.medigraphic.com